Overview

A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma

Status:
Not yet recruiting

Trial end date:
2022-09-30

Target enrollment:

Participant gender:

Summary

This is a multicenter, Phase 1/2, First-In-Human study to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Enterome

Treatments:

Vaccines